Investment

#Drug development #Investment #Life sciences #Treehill Partners #US government

Expert opinion on life sciences in a Trump/RFK era

Max Baumann, Co-Founder and Head of Execution of Treehill Partners, discusses what investors, drug developers, and the rest of the life science sector can do to prepare for the Trump/RFK era. The arrival of a new US administration generates significant industry-wide speculation and anticipation regarding new policies and agendas that may… Read More

#Business & Investment #Exclusive Content #Opinion

#Finance #Funding #Investment #Neurodegenerative disorders #Neuroscience #Private investment

New DDW Highlights episode: 11 November 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week that saw a second monoclonal antibody rejected by UK regulator NICE,… Read More

#News

#Finance #Funding #Investment #Neurodegenerative disorders #Neuroscience #Private investment

This week in drug discovery (4-8 November) 

News round-up for 4-8 November by DDW Senior Digital Content Editor Diana Spencer. This week DDW has reported on significant investment in the development of treatments for neurodegenerative diseases, but also gene therapies for CNS disorders and radioligand-based therapies for cancer. The top stories:… Read More

#News

#Dementia #Funding #Investment #Parkinson's #UK Dementia Research Institute

£20m funding offered to advance breakthroughs in dementia research

The UK Dementia Research Institute has received major new government funding to boost translational research into dementia and related neurodegenerative conditions such as Parkinson’s and motor neuron disease. The UK-wide research institute will receive an initial £20 ($25.9) million from the National Institute for Health and… Read More

#News

#Finance #Funding #Investment #Politics #Private investment #UK government

New DDW Highlights episode: 4 November 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week that saw a second monoclonal antibody rejected by UK… Read More

#News

#Drug discovery #Investment #Life sciences

Podcast: Investment trends for drug discovery and development

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Owen Smith, Partner at… Read More

#News

#Finance #Funding #Investment #Politics #Private investment #UK government

This week in drug discovery (28 Oct – 1 Nov) 

News round-up for 28 Oct – 1 Nov by DDW Senior Digital Content Editor Diana Spencer. In a week that saw a second monoclonal antibody rejected by UK regulator NICE, antibodies have been high on the news agenda. More positively, a new indication for Fasenra was approved in… Read More

#News

#4BIO Capital #Drug development #Drug discovery #Investment #Life sciences

New podcast: Investment trends for drug discovery and development

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Owen Smith, Partner at… Read More

#News

#Finance #Funding #Investment #Politics #Private investment #UK government

New DDW Highlights episode: 29 October 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With a presidential election just round the corner in the US and… Read More

#News

#Finance #Funding #Investment #Politics #Private investment #UK government

This week in drug discovery (21-25 October) 

News round-up for 21-25 October by DDW Senior Digital Content Editor Diana Spencer. With a presidential election just round the corner in the US and a new UK budget on the way, financial support for life sciences is high on the agenda, so the news round-up this week… Read More

#News

#Cystic fibrosis #Investment #LifeArc #UK

UK cystic fibrosis network to accelerate new therapeutics

LifeArc and Cystic Fibrosis Trust are jointly investing £15 million to establish a network of research hubs that will accelerate the discovery of novel diagnostics and therapeutics for lung infections. The Translational Innovation Hub Network for Lung Health and Infection will consist of four Innovation Hubs,… Read More

#News

GBP pound sterling funding
#Biopharmaceuticals #Biotechnology #Finance #Investment #mRNA #Novo Holdings #Oxford Nanopore Technologies

Investing in a new generation of molecular analysis technology 

Novo Holdings has announced a £5 million investment in Oxford Nanopore Technologies as part of an equity issue and intends to add to this investment over time, with further purchases in the secondary market, subject to availability and price (among other factors).  Oxford Nanopore has developed a… Read More

#Business & Investment #News

Image of the earth showing the UK and Scandinavia
#ABPI #Drug discovery #Investment #Life sciences #Medicines Discovery Catapult (MDC)

Why the UK needs to nurture a fit-to-fund life sciences sector 

Professor Chris Molloy, CEO of Medicines Discovery Catapult (MDC), writes about the state of the UK’s drug discovery sector, exploring economic challenges and what is needed to support the country’s rich life sciences talent.   We should all be proud of and inspired by the UK life… Read More

#Exclusive Content

#Element Biosciences #Fundraising #Gene sequencing #Investment #Multi-omics

Element Biosciences raises over $277 million

Element Biosciences has announced over $277 million in Series D investment to support continued development of its DNA sequencing and multi-omics technologies. The oversubscribed round was led by Wellington Management with participation from new and existing investors, including Samsung Electronics, Fidelity, Foresite Capital, funds and accounts… Read More

#Business & Investment #News